M
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Price:
5.2 USD
-0.38%
Market Closed
Updated:
May 18, 2024
Monte Rosa Therapeutics Inc
Operating Expenses
|
Monte Rosa Therapeutics Inc
Operating Expenses Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
M
|
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
|
Operating Expenses
-$143.3m
|
CAGR 3-Years
-72%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Expenses
-$20.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Expenses
-$12.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Expenses
-$12.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Expenses
-$4.7B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Expenses
-$7.3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-19%
|
See Also
What is Monte Rosa Therapeutics Inc's Operating Expenses?
Operating Expenses
-143.3m
USD
-143.3m
USD
Based on the financial report for Dec 31, 2023, Monte Rosa Therapeutics Inc's Operating Expenses amounts to -143.3m USD.
What is Monte Rosa Therapeutics Inc's Operating Expenses growth rate?
Operating Expenses CAGR 3Y
-72%
-72%
Over the last year, the Operating Expenses growth was -28%. The average annual Operating Expenses growth rates for Monte Rosa Therapeutics Inc have been -72% over the past three years .
You don't have any saved screeners yet
